


**Amendments To The Claims:**

1. (Original) A compound of formula:



or the pharmaceutically acceptable salts or esters thereof, wherein

R<sup>1</sup> is selected from the group consisting of

H,

lower alkyl that optionally may be substituted with a group selected from OR<sup>6</sup>,  
cycloalkyl, and NR<sup>7</sup>R<sup>8</sup>,

cycloalkyl,

COR<sup>9</sup>, and

SO<sub>2</sub>R<sup>10</sup>;

R<sup>2</sup> is selected from the group consisting of

H,

F,

Cl, and

CH<sub>3</sub>;

R<sup>5</sup> is selected from the group consisting of

H,  
lower alkyl, which optionally may be substituted with a group selected from  
OR<sup>6</sup> and NR<sup>7</sup>R<sup>8</sup>,

OR<sup>11</sup>,  
NR<sup>12</sup>R<sup>13</sup>,  
halogen,  
NO<sub>2</sub>,  
CONR<sup>6</sup>R<sup>9</sup>,  
NHSO<sub>2</sub>R<sup>14</sup>,  
CN  
S-lower alkyl,  
OCF<sub>3</sub>, and  
OCHF<sub>2</sub>,

R<sup>3</sup> and R<sup>4</sup> taken together with the two carbons and the bond between them from the benzene ring (D) to which R<sup>3</sup> and R<sup>4</sup> are attached form a ring system having up to two additional rings, each of said rings having 5-7 atoms, and the ring attached to the benzene ring (D) optionally including one or more hetero atoms and being optionally substituted by lower alkyl,

R<sup>6</sup> and R<sup>9</sup> are independently selected from the group consisting of  
H, and  
lower alkyl that optionally may be substituted by OH and halogen;

R<sup>7</sup> and R<sup>8</sup> are independently selected from the group consisting of  
H, and  
lower alkyl that optionally may be substituted by OR<sup>6</sup>,

or, alternatively, R<sup>7</sup> is H and R<sup>8</sup> is OH,

or, alternatively,  $\text{NR}^7\text{R}^8$  can optionally form a ring having 5-6 atoms, said ring optionally including one or more additional hetero atoms and being optionally substituted by the group consisting of one or more of  $\text{OR}^6$  and lower alkyl which itself may be optionally substituted by OH;

$\text{R}^{10}$  is selected from the group consisting of  
lower alkyl which optionally may be substituted by one or more chlorine or fluorine, and

$\text{NH}_2$ ;

$\text{R}^{11}$  is selected from the group consisting of  
H, and  
lower alkyl that optionally may be substituted by  $\text{OR}^6$ , COOH, halogen and  $\text{NR}^{15}\text{R}^{16}$ ;

$\text{R}^{12}$  and  $\text{R}^{13}$  are independently selected from the group consisting of  
H,  
lower alkyl that optionally may be substituted with a group selected from  $\text{OR}^6$ , COOH and  $\text{NR}^{15}\text{R}^{16}$ ,

$\text{COR}^{17}$ , and  
 $\text{SO}_2\text{R}^{18}$ ,

provided that only one of  $\text{R}^{12}$  and  $\text{R}^{13}$  is  $\text{COR}^{17}$  or  $\text{SO}_2\text{R}^{18}$ ,

or alternatively  $\text{NR}^{12}\text{R}^{13}$  can optionally form a ring having 5-6 atoms, said ring optionally including one or more additional hetero atoms and being optionally

substituted by the group consisting of one or more of  $OR^6$  and lower alkyl which itself may be optionally substituted by OH;

$R^{14}$  is lower alkyl;

$R^{15}$  and  $R^{16}$  are independently selected from the group consisting of  
H, and  
lower alkyl that optionally may be substituted by OH,

or alternatively  $NR^{15}R^{16}$  can optionally form a ring having 5-6 atoms, said ring optionally including one or more additional hetero atoms and being optionally substituted by the group consisting of one or more of  $OR^6$  and lower alkyl which itself may be optionally substituted by OH;

$R^{17}$  is selected from the group consisting of  
H, and  
lower alkyl which optionally may be substituted with a group selected from  
OH, COOH and  $NR^{15}R^{16}$ ; and

$R^{18}$  is lower alkyl.

2. (Original) The compound of claim 1 wherein  $R^1$  is selected from the group consisting of H,  $CH_2CH_2OH$ ,  $CH_2CH_2CH_2OH$ ,  $CH_3CO-$ ,  $CH(CH_3)_2$ ,  $CH_2CH(CH_3)_2$ , cyclopropylmethyl and  $CH_3$ .

3. (Original) The compound of claim 2 wherein  $R^1$  is selected from the group consisting of H, methyl,  $CH_2CH_2CH_2OH$  and  $CH(CH_3)_2$ .

4. (Original) The compound of claim 1 wherein  $R^2$  is selected from the group consisting of H and fluorine.

5. (Original) The compound of claim 4 wherein  $R^2$  is H.
6. (Original) The compound of claim 2 wherein  $R^2$  is selected from the group consisting of H and fluorine.
7. (Original) The compound of claim 3 wherein  $R^2$  is H.
8. (Original) The compound of claim 1 wherein  $R^3$  and  $R^4$  taken together with the benzene ring to which they are attached form a polycyclic ring system.
9. (Original) The compound of claim 8 wherein the ring system is selected from the group consisting of 2-dibenzofuranyl, 1,3-benzodioxol-5-yl, 2,3-dihydro-1,4-benzodioxin-6-yl, and 3,4-dihydro-2H-1,5-benzodioxepin-7-yl.
10. (Original) The compound of claim 6 wherein  $R^3$  and  $R^4$  taken together with the benzene ring to which they are attached form a polycyclic ring system.
11. (Original) The compound of claim 7 wherein  $R^3$  and  $R^4$  taken together with the benzene ring to which they are attached form a polycyclic ring system.
12. (Original) The compound of claim 10 wherein the ring system selected from the group consisting of 2-dibenzofuranyl, 1,3-benzodioxol-5-yl, 2,3-dihydro-1,4-benzodioxin-6-yl, or 3,4-dihydro-2H-1,5-benzodioxepin-7-yl.
13. (Original) The compound of claim 11 wherein the ring system selected from the group consisting of 2-dibenzofuranyl, 1,3-benzodioxol-5-yl, 2,3-dihydro-1,4-benzodioxin-6-yl, or 3,4-dihydro-2H-1,5-benzodioxepin-7-yl.

14. (Original) The compound of claim 8 which is selected from the group consisting of:

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](2,3-dihydro-1,4-benzodioxin-6-yl)methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](1,3-benzodioxol-5-yl)methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](3,4-dihydro-2H-1,5-benzodioxepin-7-yl)methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](2-dibenzofuranyl)methanone,

[4-Amino-2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](1,3-benzodioxol-5-yl)methanone,

[4-Amino-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl](2,3-dihydro-1,4-benzodioxin-6-yl)methanone,

[4-Amino-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl](1,3-benzodioxol-5-yl)methanone,

1-Acetyl-4-[4-[4-amino-5-[(1,3-benzodioxol-5-yl)carbonyl]-2-thiazolyl]amino]phenyl]piperazine, and

[4-Amino-2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl] (2,3-dihydro-1,4-benzodioxin-6-yl)methanone.

15. (Original) The compound of claim 8 which is selected from the group consisting of:

[4-Amino-2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl] (2,3-dihydro-1,4-benzodioxin-5-yl)methanone,

(4-Amino-2-{4-[4-(2-methoxy-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-benzo[1,3]dioxol-5-yl-methanone,

4-Amino-2-{4-[4-(2-methoxy-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanone,

{4-Amino-2-[4-(4-sec-butyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-benzo[1,3]dioxol-5-yl-methanone,

{4-Amino-2-[4-(4-sec-butyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanone,

{4-Amino-2-[4-(4-cyclopentyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-benzo[1,3]dioxol-5-yl-methanone,

{4-Amino-2-[4-(4-cyclopentyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanone,

{4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-benzo[1,3]dioxol-5-yl-methanone, and

{4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanone.

16. (Original) The compound of claim 1 wherein  $R^5$  is selected from the group consisting of H and F.


17. (Original) The compound of claim 16 wherein  $R^5$  is F.

18. (Original) The compound of claim 10 wherein  $R^5$  is F.

19. (Original) The compound of claim 13 wherein  $R^5$  is F.

20. (Original) The compound of claim 16 wherein  $R^5$  is H.

21. (Original) A compound of formula:



or the pharmaceutically acceptable salts or esters thereof, wherein

$R^1$  is selected from the group consisting of

H, and

lower alkyl that optionally may be substituted by  $OR^6$ ;

$R^2$  is selected from the group consisting of H and F;



$R^3$  and  $R^4$  taken together with the two carbons and the bond between them from the benzene ring (D) to which  $R^3$  and  $R^4$  are attached form a ring system having up to two additional rings, each of said rings having 5-7 atoms, and the ring attached to the benzene ring (D) optionally including one or more hetero atoms and being optionally substituted by lower alkyl,

$R^5$  is selected from the group consisting of

H,  
 $OR^{11}$ , and  
F;

$R^6$  is selected from the group consisting of

H, and  
methyl;

$R^{11}$  is selected from the group consisting of

H, and  
lower alkyl that optionally may be substituted by a group selected from  $OR^6$ ,  
COOH, halogen and  $NR^{15}R^{16}$ ;

$R^{12}$  and  $R^{13}$  are independently selected from the group consisting of

H,  
lower alkyl that optionally may be substituted with a group selected from  $OR^6$ ,  
COOH and  $NR^{15}R^{16}$ ,

or alternatively  $NR^{12}R^{13}$  can optionally form a ring having 5-6 atoms, said ring optionally including one or more additional hetero atoms and being optionally substituted by the group consisting of one or more of  $OR^6$  and lower alkyl which itself may be optionally substituted by OH; and

$R^{15}$  and  $R^{16}$  are independently selected from the group consisting of

H, and

lower alkyl that optionally may be substituted by OH,

or alternatively  $\text{NR}^{15}\text{R}^{16}$  can optionally form a ring having 5-6 atoms, said ring optionally including one or more additional hetero atoms and being optionally substituted by the group consisting of one or more of  $\text{OR}^6$  and lower alkyl which itself may be optionally substituted by OH.

22. (Original) A pharmaceutical composition comprising as an active ingredient an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

23. (Original) The pharmaceutical composition of claim 22 which is suitable for parenteral administration.

24. (Canceled)